Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sagimet Biosciences Inc. filings document a clinical-stage biopharmaceutical issuer with Series A common stock listed on the Nasdaq Global Market and emerging growth company status. Recent 8-K reports cover financial results, preliminary financial information, Regulation FD investor presentations, a material underwriting agreement and related capital-structure disclosures, and executive leadership changes.
The company’s proxy materials describe annual meeting voting matters, stockholder procedures, board-related items, and governance proposals. Its disclosures also track use-of-proceeds language, clinical-development updates for FASN inhibitor programs, and public-company reporting matters.
Sagimet Biosciences Inc. director George Kemble reported option exercises and a share sale in Series A Common Stock. On August 14, 2026, he exercised stock options covering 326,618 and 24,369 shares at an exercise price of $6.36 per share, receiving the same number of Series A Common shares. That same day, he sold 350,987 Series A Common shares at a weighted average price of $10.2328 per share, in multiple trades between $9.95 and $10.57. These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 21, 2025, and the option was fully vested and exercisable as of the transaction date.
SGMT affiliate George Kemble filed a notice of proposed sales of company common stock. The filing lists up to 350,987 shares to be sold on or about 08/14/2026 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $3,257,159.36. SGMT had 61,591,159 common shares outstanding as of this notice. The filing also records prior Rule 10b5-1 plan sales by Kemble over the past three months, including 20,206 shares on 08/11/2026 for $201,146.40 and 18,844 shares on 07/20/2026 for $140,529.13, and describes the planned sale as following an exercise of stock options for cash.
Sagimet Biosciences Inc. received a Schedule 13G reporting that a group of related investment entities led by Balyasny Asset Management L.P. beneficially owns a significant minority stake in its Series A common stock. The filing states that these reporting persons may be deemed to beneficially own 3,626,113 shares.
The shares are held directly by Atlas Diversified Master Fund, Ltd. with 1,126,113 shares and Atlas Private Holdings (Cayman) Ltd. with 2,500,000 shares, both investment management clients of Balyasny Asset Management L.P. Each reporting person is listed with sole voting and dispositive power over 3,626,113 shares and no shared power.
The stake represents approximately 5.93% of Sagimet’s outstanding common stock, based on 61,184,313 shares outstanding as of May 5, 2026, as cited from Sagimet’s Form 10-Q. This positions the Balyasny complex as a holder of more than 5% of the company’s equity.
Sagimet Biosciences Inc. reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for its fatty acid synthase inhibitor denifanstat in moderate to severe acne. The FDA also issued a “Study May Proceed” letter for a planned Phase 3 clinical trial of denifanstat in this indication.
This clearance allows Sagimet Biosciences to move forward with Phase 3 testing of denifanstat in patients with moderate to severe acne, advancing the program into a late-stage clinical development phase in the United States.
Sagimet Biosciences Inc. director George Kemble reported an option exercise-and-sale transaction in Series A Common Stock. On August 11, 2026, he exercised stock options covering 20,206 shares at an exercise price of $6.36 per share and received an equivalent number of Series A Common shares. On the same date, he sold 20,206 shares of Series A Common Stock at a weighted average price of $9.9548 per share in multiple trades priced between $9.95 and $9.99. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on August 21, 2025, and that the options involved were fully vested and exercisable as of the transaction date.
SGMT insider George Kemble filed to sell common stock under a Rule 10b5-1 trading plan. The filing lists up to 20,206 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $193,371.42, to be sold for cash on or after August 11, 2026 following an exercise of stock options. It also notes a prior 10b5-1 sale of 18,844 shares of common stock on July 20, 2026 for $140,529.13.
Sagimet Biosciences Inc. reported second-quarter 2026 results and pipeline progress focused on dermatology. For the quarter ended June 30, 2026, the company recorded a net loss of $13.9 million, compared with $10.4 million a year earlier, as it increased R&D investment.
Research and development expense was $11.5 million versus $7.2 million, while general and administrative expense was broadly flat at $4.3 million. A March–April 2026 equity financing generated $175.0 million of gross proceeds, lifting cash, cash equivalents and marketable securities to $257.6 million as of June 30, 2026, which Sagimet expects to fund operations through 2028, including Phase 3 denifanstat acne data readout and NDA submission.
Denifanstat met all primary and secondary endpoints in a Phase 3 acne trial in China, where an NDA was accepted in December 2025. Sagimet plans a U.S. registrational Phase 3 acne trial in the second half of 2026 and is running a first-in-human Phase 1 trial of follow-on FASN inhibitor TVB-3567.
Sagimet Biosciences Inc. reported a net loss of $13.9 million for the quarter ended June 30, 2026, compared with $10.4 million a year earlier, as it advanced its fatty acid synthase (FASN) inhibitor pipeline. For the first six months of 2026, net loss was $24.6 million versus $28.6 million in 2025, reflecting lower year-to-date research and development spending.
Cash, cash equivalents and marketable securities totaled $257.6 million at June 30, 2026, up sharply from $116.5 million in total assets at year-end 2025, driven by an April 2026 underwritten offering of 29,166,700 Series A shares at $6.00 per share, providing $163.9 million in net proceeds. Total assets were $263.4 million and stockholders’ equity was $256.2 million, with minimal liabilities.
Management expects existing liquidity to fund operating expenses for at least 12 months. The company remains a clinical-stage biotech with no product revenue, focusing on lead candidate denifanstat for acne and MASH, and TVB-3567 in a Phase 1 acne trial, while MASH combination work will not move beyond Phase 2 readiness without non-dilutive funding.
BlackRock, Inc. reports a passive ownership position in Sagimet Biosciences Inc. (Class A Stock) on a Schedule 13G. As of June 30, 2026, BlackRock’s reporting business units beneficially owned 4,751,186 Class A shares, representing 7.8% of the class.
BlackRock has sole voting power over 4,690,270 shares and sole dispositive power over all 4,751,186 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Sagimet’s outstanding common shares.
Sagimet Biosciences Inc. President & CEO David Happel sold 64,051 shares of Series A Common Stock on July 20, 2026 at a weighted average price of $7.7605 per share to cover tax withholding obligations from vesting restricted stock units. These automatic, non-discretionary sales occurred in multiple trades between $7.76 and $7.94 and left him holding 741,570 shares directly.